Clinical trial No longer in our active list Observational Ages 18 to 64

Investigating the effects of Ocrevus on cognitive fatigue in multiple sclerosis

Official title: A Biomarker for Cognitive Fatigue Using Functional Imaging in MS

Run by Kessler Foundation · NCT04448977 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing how the medication Ocrevus affects cognitive fatigue in people with relapsing-remitting multiple sclerosis to see if it helps them think better during challenging tasks.

Quick facts

Study typeObservational
Ages18 Years to 64 Years
SexAll
Enrollment60 (estimated)
SponsorKessler Foundation
Academic / other
Locations1 site (West Orange, New Jersey)
Trial IDNCT04448977 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-64 with relapsing-remitting multiple sclerosis who have been newly prescribed a disease-modifying medication.

Probably not a fit

Patients with significant neurological events, psychiatric illnesses, or those unable to undergo MRI may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research examines how the disease-modifying medication Ocrevus affects cognitive fatigue in individuals with relapsing-remitting multiple sclerosis (RRMS). The study utilizes functional MRI (fMRI) to assess changes in brain activity related to cognitive fatigue during demanding tasks. Participants will include those newly prescribed Ocrevus or Copaxone, as well as healthy volunteers. The research aims to understand how cognitive fatigue evolves with treatment duration and its impact on specific brain regions.

Why it matters

Potential benefit: If successful, this study could lead to improved management strategies for cognitive fatigue in patients with multiple sclerosis.

How similar studies have gone: Other studies have explored cognitive fatigue in multiple sclerosis, but this specific investigation into Ocrevus's effects is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 18-64.
* Relapsing remitting multiple sclerosis
* Been newly prescribed a new disease modifying medication for MS (either Ocrevus or Copaxone)
* or healthy volunteer who can speak English fluently.

Exclusion Criteria:

* History of head injury, stroke, seizures, or any other significant neurological event other than MS
* Flare up of MS symptoms within the past month.
* History of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder.
* Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments.
* left handed.
* Not able to have an MRI

Where it's running

  • Kessler Foundation
    West Orange, New Jersey, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.